Teleflex Incorporated (TFX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Teleflex Incorporated

NYSE•Healthcare•Medical Instruments & Supplies

$125.21-0.38(<0.01%)Market open

Market Cap

$5.42B

P/S

3.3x

P/B

1.9x

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

How this company scores

WeakMetricSide Score: 25/100

Strongest: Balance Sheet & Red Flags (10/25); weakest: Growth (4/25).

Profitability5/25

Growth4/25

Balance Sheet & Red Flags10/25

Cash & Earnings Quality6/25

Strengths

Improving marginsNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 27.6x5y range 22.9x – 117.9x

Currently near its 16-quarter median.

P/S · 3.3x5y range 1.7x – 6.6x

Currently near its 20-quarter median.

P/B · 1.9x5y range 1.2x – 5.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 306.2% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -0.2x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $5.42B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.63B
Q. Revenue: $570.33M
TTM EBITDA: $78.76M
TTM Op. Income: $-69.50M
Q. Op. Income: $72.82M
TTM Net Income: $-1.03B
Q. Net Income: $99.69M
EPS: $2.29
Shares Out.: $43.56M

$1.63B in TTM revenue declined 46.4% YoY, reaching $570.33M last quarter. TTM EBITDA of $78.76M and TTM operating income of $-69.50M show growth is flowing through to the bottom line. However, net income is negative at $1.03B — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 58.2%
EBITDA Margin: 21.5%
Op. Margin: 12.8%
Net Margin: 17.5%

Op. margin of 12.8% is down 7.1% YoY — costs are rising relative to revenue. Net margin at 17.5% and gross margin of 58.2% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 3.3x
P/B Ratio: 1.9x

P/S of 3.3x and P/B of 1.9x. Across the last 4 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $6.79B
Cash: $300.16M
Long-Term Debt: $2.72B
Book Value: $2.90B
D/E Ratio: 0.9
Debt/EBITDA: 22.2

With $6.79B in assets and $2.72B in long-term debt, D/E is 0.9and book value is $2.90B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 4 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $91.90M
TTM Free Cash Flow: $90.63M
FCF Margin: 5.6%
FCF / Net Income: -0.1

TTM FCF of $90.63M on $91.90M in operating cash flow. The FCF / Net Income ratio of -0.1x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is down 77% — an improving trend.